CureVac N.V. (CVAC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 10:00AM EDT. Market open.
| Previous close | 8.04 |
| Open | 8.00 |
| Bid | 8.14 x 800 |
| Ask | 8.24 x 800 |
| Day's range | 8.00 - 8.23 |
| 52-week range | 6.99 - 52.11 |
| Volume | |
| Avg. volume | 419,700 |
| Market cap | 1.53B |
| Beta (5Y monthly) | 3.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 16 Nov 2022 - 21 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.16 |
- Zacks
Bet on These 4 Biotech Stocks With Bright Prospects
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
- Simply Wall St.
The past year for CureVac (NASDAQ:CVAC) investors has not been profitable
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
- Zacks
Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
© 2022 Yahoo. All rights reserved.
